SCHEMBL976427

SCHEMBL976427

N#Cc1cccc(Br)c1NCC(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 1/20 0.39
MELK Q14680 1/20 0.38
GAA P10253 4/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CXCR2 P25025 4/20 0.35
CXCR1 P25024 2/20 0.35
MAPT P10636 2/20 0.34
DYRK1A Q13627 1/20 0.33
LDHA P00338 1/20 0.33
LDHB P07195 1/20 0.33
ADRB3 P13945 1/20 0.33
TSPO P30536 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
SLC9A1 P19634 1/20 0.32
TSHR P16473 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12922133 0.84 PIP4K2A (0.32) PIP4K2AMELK
SCHEMBL12948524 0.78 PRKCI (0.34) PIP4K2AMELK
SCHEMBL29468705 0.76 DYRK1A (0.38) GAADYRK1ATSHRKDM4EALDH1A1
SCHEMBL28315214 0.76 DYRK1A (0.38) GAADYRK1ATSHRKDM4EALDH1A1
SCHEMBL22979056 0.74 GAA (0.41) GAACXCR2CXCR1MAPTDYRK1A
SCHEMBL5989445 0.74 ALDH1A1 (0.42) PIP4K2AMELKGAASMN1; SMN2CXCR2
SCHEMBL5025117 0.73 BLM (0.41) PIP4K2AMELKGAASMN1; SMN2CXCR2
SCHEMBL30393661 0.71 GAA (0.42) GAASMN1; SMN2CXCR2CXCR1MAPT
SCHEMBL1848870 0.70 NPC1 (0.48) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL977210 0.70 PIP4K2A (0.39) PIP4K2AMELKGAASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664233-B2 Substituted 5H-pyrimido[5,4-B]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2014-03-04 US disclosed
EP-2104675-B1 SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM MEDICINES CO LEIPZIG GMBH (DE) 2012-10-31 EP disclosed
US-20110021511-A1 SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2011-01-27 US disclosed
EP-2104675-A1 SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM The Medicines Company (Leipzig) GmbH (DE) 2009-09-30 EP disclosed
WO-2008077631-A1 SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021511-A1 SUBSTITUTED 5H-PYRIMIDO[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM BCL6, BCL3, BCL6B PIP4K2A 1944/4885MELK 2168/4885GAA 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.